Boston Scientific Corp. will enter the nascent renal denervation space in 2013 by paying up to $425 million to acquire privately held Vessix Vascular Inc., the company announced Nov. 8.
The definitive acquisition agreement calls for an upfront payment of $125 million, plus additional clinical- and sales-based milestone payments of...